Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma

Jonathan D. Licht, Rosemary Mazanet, Patrick Loehrer, René Gonin, Karen H. Antman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Intravenous-bolus etoposide has modest activity in sarcomas when given daily for 3-5 days. Low frequent doses theoretically inhibit topoisomerase II activity over a longer duration and have been reported to have increased activity in small-cell lung cancer. A phase I trial of oral etoposide resulted in partial responses in two patients with soft-tissue sarcomas. To estimate more accurately the response rate for daily oral etoposide in sarcomas, we treated 25 patients with 50 mg/m2 per day by mouth for 21 days every 4 weeks. Treatment-related toxicity included≥grade 2 neutropenia in 6 of the 25 patients and thrombocytopenia in 3. One brief partial response was observed (4%; 95% confidence interval for true response rate, 0-11%). Disease stabilized in five patients for periods ranging from 3 to 18 months. At this dose and on this schedule, daily oral etoposide appears to have little activity against soft-tissue sarcomas.

Original languageEnglish
Pages (from-to)79-80
Number of pages2
JournalCancer Chemotherapy and Pharmacology
Volume34
Issue number1
DOIs
StatePublished - Jan 1994

Fingerprint

Etoposide
Sarcoma
Tissue
Type II DNA Topoisomerase
Small Cell Lung Carcinoma
Therapeutics
Neutropenia
Toxicity
Mouth
Appointments and Schedules
Cells
Confidence Intervals

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. / Licht, Jonathan D.; Mazanet, Rosemary; Loehrer, Patrick; Gonin, René; Antman, Karen H.

In: Cancer Chemotherapy and Pharmacology, Vol. 34, No. 1, 01.1994, p. 79-80.

Research output: Contribution to journalArticle

Licht, Jonathan D. ; Mazanet, Rosemary ; Loehrer, Patrick ; Gonin, René ; Antman, Karen H. / Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. In: Cancer Chemotherapy and Pharmacology. 1994 ; Vol. 34, No. 1. pp. 79-80.
@article{45d1c235570047bb8b131a85c5745bd5,
title = "Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma",
abstract = "Intravenous-bolus etoposide has modest activity in sarcomas when given daily for 3-5 days. Low frequent doses theoretically inhibit topoisomerase II activity over a longer duration and have been reported to have increased activity in small-cell lung cancer. A phase I trial of oral etoposide resulted in partial responses in two patients with soft-tissue sarcomas. To estimate more accurately the response rate for daily oral etoposide in sarcomas, we treated 25 patients with 50 mg/m2 per day by mouth for 21 days every 4 weeks. Treatment-related toxicity included≥grade 2 neutropenia in 6 of the 25 patients and thrombocytopenia in 3. One brief partial response was observed (4{\%}; 95{\%} confidence interval for true response rate, 0-11{\%}). Disease stabilized in five patients for periods ranging from 3 to 18 months. At this dose and on this schedule, daily oral etoposide appears to have little activity against soft-tissue sarcomas.",
author = "Licht, {Jonathan D.} and Rosemary Mazanet and Patrick Loehrer and Ren{\'e} Gonin and Antman, {Karen H.}",
year = "1994",
month = "1",
doi = "10.1007/BF00686117",
language = "English",
volume = "34",
pages = "79--80",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma

AU - Licht, Jonathan D.

AU - Mazanet, Rosemary

AU - Loehrer, Patrick

AU - Gonin, René

AU - Antman, Karen H.

PY - 1994/1

Y1 - 1994/1

N2 - Intravenous-bolus etoposide has modest activity in sarcomas when given daily for 3-5 days. Low frequent doses theoretically inhibit topoisomerase II activity over a longer duration and have been reported to have increased activity in small-cell lung cancer. A phase I trial of oral etoposide resulted in partial responses in two patients with soft-tissue sarcomas. To estimate more accurately the response rate for daily oral etoposide in sarcomas, we treated 25 patients with 50 mg/m2 per day by mouth for 21 days every 4 weeks. Treatment-related toxicity included≥grade 2 neutropenia in 6 of the 25 patients and thrombocytopenia in 3. One brief partial response was observed (4%; 95% confidence interval for true response rate, 0-11%). Disease stabilized in five patients for periods ranging from 3 to 18 months. At this dose and on this schedule, daily oral etoposide appears to have little activity against soft-tissue sarcomas.

AB - Intravenous-bolus etoposide has modest activity in sarcomas when given daily for 3-5 days. Low frequent doses theoretically inhibit topoisomerase II activity over a longer duration and have been reported to have increased activity in small-cell lung cancer. A phase I trial of oral etoposide resulted in partial responses in two patients with soft-tissue sarcomas. To estimate more accurately the response rate for daily oral etoposide in sarcomas, we treated 25 patients with 50 mg/m2 per day by mouth for 21 days every 4 weeks. Treatment-related toxicity included≥grade 2 neutropenia in 6 of the 25 patients and thrombocytopenia in 3. One brief partial response was observed (4%; 95% confidence interval for true response rate, 0-11%). Disease stabilized in five patients for periods ranging from 3 to 18 months. At this dose and on this schedule, daily oral etoposide appears to have little activity against soft-tissue sarcomas.

UR - http://www.scopus.com/inward/record.url?scp=0028277455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028277455&partnerID=8YFLogxK

U2 - 10.1007/BF00686117

DO - 10.1007/BF00686117

M3 - Article

C2 - 8174207

AN - SCOPUS:0028277455

VL - 34

SP - 79

EP - 80

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -